loading
Biovista
Website:

Biovista is an SME with extensive expertise in leveraging Augmented Intelligence (AuI) and in-silico technologies to address healthcare challenges and drug development issues. The company’s advanced data analysis platform (COSS) and its component tools (Biovista Vizit) integrate, analyze and visualize diverse types of biomedical and clinical data on top of the scientific literature, in order to support subject matter experts. Biovista platform has been used to elucidate the molecular basis of diseases, analyze the mechanism of action (MoA) of drugs, predict new indications for existing drugs (drug repositioning), identify unanticipated adverse drug reactions and discover biomarkers for clinical trial optimization. Collaborators include, among others, pharmaceutical companies, biotechnology and reagent companies, regulatory agencies (FDA) and patient advocacy groups from the life-sciences industry as well as large IT companies active in AI and big data analytics. Biovista is the recipient of multiple EU R&D project awards through which it pursues state-of-the-art solutions in its areas of interest, including adverse event prediction and development of Adverse Outcome Pathways (AOPs), in which, the company has been leading the harmonization of the various fields with industry-standard ontologies and controlled vocabularies.